Literature DB >> 16478854

Discriminating measures and normal values for expiratory obstruction.

James E Hansen1, Xing-Guo Sun, Karlman Wasserman.   

Abstract

OBJECTIVES: To develop mean and 95% confidence limits for the lower limit of normal (LLN) values for forced expiratory volume in 3 s (FEV3)/FVC ratio for Latin, black, and white adults; to ascertain comparative variability of the FEV1/FVC ratio, the FEV3/FVC ratio, and forced expiratory flow, midexpiratory phase (FEF(25-75)) in never-smoking adults; to evaluate their utility in measuring the effect of smoking on airflow limitation; and to develop and use the fraction of the FVC that had not been expired during the first 3 s of the FVC (1 - FEV3/FVC) to identify the growing fraction of long-time-constant lung units.
DESIGN: Analysis of the Third National Health and Nutrition Examination Survey (NHANES III) database of never-smokers and current smokers. PARTICIPANTS: A total of 5,938 adult never-smokers and 3,570 current smokers from NHANES III with spirometric data meeting American Thoracic Society standards. MEASUREMENTS AND
RESULTS: After establishing new databases for never-smokers and current smokers, we quantified the mean and LLN values of FEV3/FVC in never-smokers, and identified spirometric abnormalities in current smokers. When associated with older age, FEV3/FVC decreases and 1 - FEV3/FVC increases as FEV1/FVC decreases. On average, using these measurements, the condition of current smokers worsened about 20 years faster than that of never-smokers by middle age. If < 80% of the mean predicted FEF(25-75) was used to identify abnormality, over one quarter of all never-smokers would have been falsely identified as being abnormal. Using 95% confidence limits, 42% of 683 smokers with reduced FEV1/FVC and/or FEV3/FVC would have been judged as normal by FEF(25-75).
CONCLUSIONS: FEV1/FVC, FEV3/FVC, and 1 - FEV3/FVC characterize expiratory obstruction well. In contrast, FEF(25-75) measurements can be misleading and can cause an unacceptably large number of probable false-negative results and probable false-positive results.

Entities:  

Mesh:

Year:  2006        PMID: 16478854     DOI: 10.1378/chest.129.2.369

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  Re-Defining Lower Limit of Normal for FEV1/FEV6, FEV1/FVC, FEV3/FEV6 and FEV3/FVC to Improve Detection of Airway Obstruction.

Authors:  James E Hansen; Janos Porszasz; Richard Casaburi; William W Stringer
Journal:  Chronic Obstr Pulm Dis       Date:  2015-03-10

2.  Determinants of spirometry use and accuracy of COPD diagnosis in primary care.

Authors:  Min J Joo; David H Au; Marian L Fitzgibbon; Joanne McKell; Todd A Lee
Journal:  J Gen Intern Med       Date:  2011-06-29       Impact factor: 5.128

Review 3.  Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC.

Authors:  Daniel Hoesterey; Nilakash Das; Wim Janssens; Russell G Buhr; Fernando J Martinez; Christopher B Cooper; Donald P Tashkin; Igor Barjaktarevic
Journal:  Respir Med       Date:  2019-08-09       Impact factor: 3.415

4.  Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.

Authors:  Nathan Yee; Daniela Markovic; Russell G Buhr; Spyridon Fortis; Mehrdad Arjomandi; David Couper; Wayne H Anderson; Robert Paine; Prescott G Woodruff; Meilan K Han; Fernando J Martinez; R Graham Barr; James M Wells; Victor E Ortega; Eric A Hoffman; Victor Kim; M Bradley Drummond; Russell P Bowler; Jeffrey L Curtis; Christopher B Cooper; Donald P Tashkin; Igor Z Barjaktarevic
Journal:  Chest       Date:  2021-11-10       Impact factor: 10.262

5.  Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.

Authors:  Kirsten M Williams; Jason W Chien; Mark T Gladwin; Steven Z Pavletic
Journal:  JAMA       Date:  2009-07-15       Impact factor: 56.272

6.  A Novel Spirometric Measure Identifies Mild COPD Unidentified by Standard Criteria.

Authors:  Asli Gorek Dilektasli; Janos Porszasz; Richard Casaburi; William W Stringer; Surya P Bhatt; Youngju Pak; Harry B Rossiter; George Washko; Peter J Castaldi; Raul San Jose Estepar; James E Hansen
Journal:  Chest       Date:  2016-07-22       Impact factor: 9.410

Review 7.  N-acetylcysteine in COPD: why, how, and when?

Authors:  Claudio M Sanguinetti
Journal:  Multidiscip Respir Med       Date:  2016-02-03

8.  A Simple Measure to Assess Hyperinflation and Air Trapping: 1-Forced Expiratory Volume in Three Second / Forced Vital Capacity.

Authors:  Sermin Börekçi; Tunçalp Demir; Aslı Görek Dilektaşlı; Melahat Uygun; Nurhayat Yıldırım
Journal:  Balkan Med J       Date:  2017-04-05       Impact factor: 2.021

9.  Significances of spirometry and impulse oscillometry for detecting small airway disorders assessed with endobronchial optical coherence tomography in COPD.

Authors:  Zhu-Quan Su; Wei-Jie Guan; Shi-Yue Li; Ming Ding; Yu Chen; Mei Jiang; Xiao-Bo Chen; Chang-Hao Zhong; Chun-Li Tang; Nan-Shan Zhong
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-01

Review 10.  Techniques of assessing small airways dysfunction.

Authors:  William McNulty; Omar S Usmani
Journal:  Eur Clin Respir J       Date:  2014-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.